早期肺癌的立体定向体部放疗：活检证实及经验性治疗病变的结果
SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions.
作者信息
Wegner Rodney E, Ahmed Nissar, Hasan Shaakir, Schumacher Lana Y, Van Deusen Matthew, Colonias Athanasios
机构信息
Allegheny Health Network, Cancer Institute, Division of Radiation Oncology, Pittsburgh, PA 15212, USA.
Allegheny Health Network, Department of Thoracic Surgery, Pittsburgh, PA 15212, USA.
出版信息
Lung Cancer Manag. 2018 Apr 17;7(1):LMT01. doi: 10.2217/lmt-2018-0006. eCollection 2018 Mar.
AIM
Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation.
METHODS
We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes.
RESULTS
A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts.
CONCLUSION
SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.
目的
在此，我们比较接受有或无组织确认的肺部立体定向体部放疗（SBRT）患者的治疗结果。
方法
我们回顾了196例在10年期间因疑似（100例）或确诊的非小细胞肺癌（96例）接受肺部SBRT的患者，并比较了治疗结果。
结果
总共196例患者，中位年龄76岁，接受肺部SBRT，中位剂量48 Gy，分4次给予。中位随访时间为17个月。整个组3年时的局部控制率和总生存率分别为94%和58%。两组之间的总生存率、局部控制率、区域控制率或远处控制率没有差异。
结论
SBRT是治疗医学上无法手术的非小细胞肺癌患者的一种安全有效的治疗方法，在经验性治疗的患者中效果相当。
Zotero 插件